Drug trio found to block tumour resistance in pancreatic cancer

Drug trio found to block tumour resistance in pancreatic cancer

0 SHARES

Posted: 29 January 2026 | Drug Target Review |

A new study reports that a triple-targeted drug combination can drive complete and lasting regression of pancreatic tumours in preclinical models, potentially overcoming treatment resistance in one of the deadliest cancers.

Researchers at the Spanish National Cancer Research Centre have announced a potential breakthrough combination therapy that induces complete regression of pancreatic tumours and prevents tumour resistance in preclinical models.

The study describes a targeted combination therapy that simultaneously targets three key signalling pathways in pancreatic ductal adenocarcinoma (PDAC), the most common and lethal type of pancreatic cancer.

Triple inhibition strategy

Pancreatic cancer remains notoriously difficult to treat, with very poor survival rates and limited effective therapies. The new research aims to combat this by targeting RAF1, EGFR family receptors and STAT3 signalling – nodes that are crucial for tumour growth and survival.

According to the authors, “genetic ablation of three independent nodes involved in downstream (RAF1), upstream (EGFR) and orthogonal (STAT3) KRAS signalling pathways leads to complete and permanent regression of orthotopic PDACs induced by KRAS/TP53 mutations.”

The triple treatment combines three drugs:

... continue reading